|
Jointly provided by Impact Education, LLC and Postgraduate Institute for Medicine.
| This activity is supported by independent educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals. |
|
Wednesday, October 18, 2017
6:00 AM - 7:45 AM CT Gaylord Texan Hotel & Conference Center Room: Grapevine Ballroom A Dallas, TX Please note: No additional fee is required to attend this CME/CPE activity; however, registration to the AMCP Nexus 2017 is required. |
Held in conjunction with  AMCP Nexus 2017. |
Click here to download the slides from this symposium. Also, don't miss the live webcast on this topic. Register now at: www.ImpactEdu.net/AtopicDermatitis/ Live credit available for nurses, pharmacists, and physicians. |
|
| Atopic Dermatitis Cutting Edge Topics Include: | |
Expert Faculty Presenters
| |
|
Jeffrey D. Dunn, PharmD, MBA Vice President, Clinical Strategy and Programs and Industry Relations MagellanRx Management |
|
John Fox, MD, MHA Vice President, Associate Chief Medical Officer Medical Affairs Priority Health |
|
Alan Menter, MD Chief, Division of Dermatology Baylor University Medical Center |
|
| Who Should Attend? |
|
This activity is intended for managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending the AMCP 2017 Nexus Meeting. |
| Statement of Need / Program Overview |
|
Atopic dermatitis (AD), or eczema, is a common chronic, relapsing inflammatory skin disease marked by pruritus and skin irritation. It is associated with substantial morbidity and greatly impacts quality of life. The majority (~67%) of patients have mild disease and are adequately managed by their primary care provider (PCP). Patients with more difficult to treat disease are frequently referred to a dermatologist or other specialist. This symposium is focused on AD diagnosis and treatment, impact of emerging AD therapies, adherence to therapy, and management of the pharmacy benefit. It is specifically designed to meet the needs of health care decision makers (HCDMs) from health plans, insurers, health systems, and other payers responsible for the benefit management, therapeutic category review, and AD clinical pathway development. |
| Educational Objectives |
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
|
| Agenda |
|
Date and Time Wednesday, October 18, 2017 6:00 AM - 7:45 AM CT Gaylord Texan Hotel & Conference Center Room: Grapevine Ballroom A Dallas, TX |
| 6:00 AM |
Opening Comments and Pre-activity Assessment Jeffrey Dunn, PharmD, MBA |
| 6:05 AM |
Integrating Atopic Dermatitis Diagnosis and Treatment Guidelines with Health Plan Algorithms to Optimize Outcomes
John Fox, MD, MHA |
| 6:40 AM |
Targeted Therapies for the Treatment of Moderate-to-Severe Atopic Dermatitis Alan Menter, MD |
| 7:15 AM |
Benefit Management Strategies to Remove Barriers and Enhance Overall Value for the Treatment of Atopic Dermatitis Jeffrey D. Dunn, PharmD, MBA |
| 7:35 AM | Faculty Discussion Q&A |
| 7:45 AM | Conclusion |
|
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. Postgraduate Institute for Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Continuing Pharmacy Education |
 |
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hours (0.175 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-738-L01-P Type of Activity: Application For Pharmacists: Upon receipt of a completed activity evaluation form, you will receive an email from CEcertificate@pimed.com within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. |
|
Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity. Americans with Disabilities Act ♿ Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812. Fee Information No additional fee is required to attend this CPE/CME activity. A statement of credit will be issued only upon receipt of a completed activity evaluation. Please note: No additional fee is required to attend this CME/CPE activity; however, registration to AMCP Nexus 2017 is required. Pre-registration will close at 12:00 pm on October 17, 2017. Walk-in registration will be available at the time of the program. If you have any questions, please call (215) 619-8812 or email info@impactedu.net. |